Actuate Therapeutics (ACTU)

Its lead drug candidate is elraglusib, formerly known as 9-ING-41. Elraglusib is a small-molecule therapy designed to enter tumour cells and inhibit GSK-3 beta, an enzyme involved in signalling pathways that influence cancer cell survival, proliferation, migration, invasion, and resistance mechanisms. Because GSK-3 is connected to multiple oncogenic and inflammatory processes, Actuate is evaluating whether blocking this target can improve the effectiveness of cancer treatment, including in combination with other therapies.

As a clinical-stage company, Actuate’s value depends heavily on the progress of its trials, regulatory interactions, safety data, and the strength of evidence supporting elraglusib’s potential use in oncology. The company does not operate like a diversified pharmaceutical manufacturer with a broad portfolio of marketed drugs; instead, it is focused on advancing a targeted development programme through the clinical and regulatory process.

ACTU is therefore a high-risk biotechnology stock tied to drug development milestones. Its investment case rests on the scientific rationale for GSK-3 inhibition, the clinical performance of elraglusib in difficult-to-treat cancers, and the company’s ability to secure the capital and partnerships needed to move its pipeline forward.